Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia

被引:26
作者
Sohler, NL
Walkup, J
McAlpine, D
Boyer, C
Olfson, M
机构
[1] Montefiore Med Ctr, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA
[4] Univ Minnesota, Dept Hlth Serv Res & Policy, Minneapolis, MN USA
[5] Columbia Univ, Dept Psychiat, New York, NY USA
[6] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
关键词
D O I
10.1176/appi.ps.54.9.1258
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Applying the schizophrenia treatment guidelines established by the Patient Outcomes Research Team (PORT) project, this study evaluated whether antipsychotic medication dosage influenced patient Outcomes in routine clinical settings. Methods: The associations between discharge antipsychotic medication dosage and shortterm clinical, social, and service use outcomes were observed in a sample of 246 patients with schizophrenia or schizoaffective disorder. Results: Patient's who were given high dosages of antipsychotic medication at hospital discharge (more than 1,000 chlorpromazine milligram equivalents) had greater severity of symptoms three months af-ter discharge than patients who.were given guideline-recommended dosages (306 to 1,000 chlorpromazine milligram equivalents) (adjusted 9 mean Brief Psychiatric Rating Scale scores of 45 and'39, respectively). Patients who were given low dosages of.antipsychotic medication at hospital discharge (less than 300 chlorpromazine milligram equivalents) Were less likely - to report, side effects (adjusted OR=.24) and slightly more likely to be non adherent (21 percent of those-within the recommended dose range compared with 39 percent Of the those with low doses, not statistically significant after Bonferroni correction). No other differences related to medication' dosage were observed in patient outcomes. Conclusions: Treatment that falls within antipsychotic' in. c dication dosage guidelines is associated with improvement in a lim'9 ited, but critical, range of short-term patient outcomes in routine clinical settings.
引用
收藏
页码:1258 / 1263
页数:6
相关论文
共 34 条
[1]   CONTROLLED TRIAL OF PHENOTHIAZINE WITHDRAWAL IN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
ANDREWS, P ;
HALL, JN ;
SNAITH, RP .
BRITISH JOURNAL OF PSYCHIATRY, 1976, 128 (MAY) :451-455
[2]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[3]  
[Anonymous], 1996, Journal of Clinical Psychiatry
[4]   MEASUREMENT OF PESSIMISM - HOPELESSNESS SCALE [J].
BECK, AT ;
WEISSMAN, A ;
LESTER, D ;
TREXLER, L .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1974, 42 (06) :861-865
[5]   STUDYING INPATIENT TREATMENT PRACTICES IN SCHIZOPHRENIA - AN INTEGRATED METHODOLOGY [J].
BOYER, CA ;
OLFSON, M ;
KELLERMANN, SL ;
HANSELL, S ;
WALKUP, J ;
ROSENFIELD, S ;
MECHANIC, D .
PSYCHIATRIC QUARTERLY, 1995, 66 (04) :293-320
[6]   The schizophrenia PORT pharmacological treatment recommendations: Conformance and implications for symptoms and functional outcome [J].
Buchanan, RW ;
Kreyenbuhl, J ;
Zito, JM ;
Lehman, A .
SCHIZOPHRENIA BULLETIN, 2002, 28 (01) :63-73
[7]   Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia [J].
Chen, RS ;
Nadkarni, PM ;
Levin, FL ;
Miller, PL ;
Erdos, J ;
Rosenheck, RA .
PSYCHIATRIC SERVICES, 2000, 51 (06) :791-794
[8]  
Emsley RA, 1999, J CLIN PSYCHIAT, V60, P10
[9]   Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction [J].
Fenton, WS ;
Kane, JM .
SCHIZOPHRENIA BULLETIN, 1997, 23 (04) :563-565
[10]   SIMULTANEOUS TESTS OF MANY HYPOTHESES IN EXPLORATORY RESEARCH [J].
GROVE, WM ;
ANDREASEN, NC .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1982, 170 (01) :3-8